Pharmaceutical Formulations Comprising Voriconazole and Processes for Preparation Thereof
AssigneeNanjing Cavendish Bio-Engineering Technology Co., Ltd.
InventorYongxiang Xu
Life of this patent
Estimating the term…
Abstract
The present invention provides a pharmaceutical formulation comprising voriconazole or a pharmaceutically acceptable derivative thereof, and an excipient of formula (I), i.e., monomethoxy poly(ethylene glycol)-poly (D,L-lactic acid) block copolymers (mPEG-PDLLA). The pharmaceutical formulation of the present invention has been shown to be stable and safe by experiments.
Claims21
1-13. (canceled)
A pharmaceutical formulation comprising voriconazole or a pharmaceutically acceptable derivative thereof and an excipient “monomethoxy poly (ethylene glycol)-poly(D,L-lactic acid) block copolymers (mPEG-PDLLA)” of formula (I) as following:
- molecular formula:
- CH3(C2H4O)a(C6H8O4)bOH
- wherein, a in the copolymer is 30˜55, b is 10˜55, and the average molecular weight is in the range of 2800˜10000.
A lyophilized injection comprising voriconazole or a pharmaceutically acceptable derivative thereof and copolymers of formula (I) as following:
- molecular formula:
- CH3(C2H4O)a(C6H8O4)bOH
- wherein, a in the copolymer is 30˜55, b is 10˜55, the average molecular weight is in the range of 2800˜10000, the content of voriconazole or a pharmaceutically acceptable derivative thereof, based on voriconazole, is 2.0%˜20.0% by weight;
- and the weight ratio of voriconazole or a pharmaceutically acceptable derivative thereof, based on voriconazole, to copolymers of formula (I) is 1:5˜1:50.
Dependencies are inferred from the claim text.